VERTEX PHARMACEUTICALS (EUROPE) LIMITED
The company operates as the European research and development subsidiary of the Nasdaq-listed American biopharmaceutical group Vertex Pharmaceuticals Incorporated.
Get an alert when VERTEX PHARMACEUTICALS (EUROPE) LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£430m
USD 579,830,000
-24% vs 2024
Net assets
£3.5bn
USD 4,763,933,000
+3.4% highest in 3 filed years
Employees
735
+3.2% highest in 3 filed years
Profit before tax
£959m
USD 1,291,860,000
-14.2% vs 2024
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
1 PSC ceased in last 24 months
Significant control changed hands — see the Ownership section.
Net assets
3-year trend · vs Industrials median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | £7,601,535,927 | £10,076,400,828 | £9,486,952,134 | -5.8% | |
| Operating profit | £774,972,545 | £1,135,705,189 | £959,663,080 | -15.5% | |
| Profit before tax | £813,413,869 | £1,117,205,508 | £958,708,720 | -14.2% | |
| Net profit | £561,984,625 | £853,561,764 | — | — | |
| Cash | £367,678,852 | £566,060,968 | £430,300,557 | -24% | |
| Total assets less current liabilities | £2,925,464,387 | £3,521,135,785 | £3,628,346,568 | +3% | |
| Net assets | £2,925,464,387 | £3,418,532,315 | £3,535,386,271 | +3.4% | |
| Equity | £2,925,464,387 | £3,418,532,315 | £3,535,386,271 | +3.4% | |
| Average employees | 643 | 712 | 735 | +3.2% | |
| Wages | £71,140,571 | £87,860,554 | £93,415,955 | +6.3% | |
| Directors' remuneration | £913,869 | £946,355 | £824,490 | -12.9% | |
| Directors' pension contributions | £26,671 | £28,653 | £28,200 | -1.6% | |
| Highest paid director | £465,955 | £497,453 | £482,375 | -3% |
Figures converted to GBP from USD at 0.742 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Operating margin | 10.2% | 11.3% | 10.1% | |
| Net margin | 7.4% | 8.5% | — | |
| Return on capital employed | 26.5% | 32.3% | 26.4% | |
| Gearing (liabilities / total assets) | 31.0% | 32.3% | 26.0% | |
| Current ratio | 2.04x | 2.29x | 3.03x | |
| Interest cover | 26.84x | 21.21x | 34.53x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- VERTEX PHARMACEUTICALS (EUROPE) LIMITED 1994-08-12 → present
- INTERCEDE 1083 LIMITED 1994-03-11 → 1994-08-12
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- BDO LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Company's ultimate parent, Vertex Pharmaceuticals Inc., has confirmed in writing that it will support the Company to continue trading and enable it to meet its liabilities as they fall due for at least 12 months from the approval of these financial statements.”
Group structure
- VERTEX PHARMACEUTICALS (EUROPE) LIMITED · parent
- Vertex Pharmaceuticals (Ireland) Limited 100%
- Vertex Pharmaceuticals (Sweden) AB 100%
- Vertex Pharmaceuticals (CH) GmbH 100%
- Vertex Pharmaceuticals (Portugal) Unipessoal Lda 100%
- Vertex Pharmaceuticals GmbH 100%
- Vertex Pharmaceuticals (U.K.) Limited 100%
- Vertex Pharmaceuticals Single Member Societe Anonyme 100%
Significant events
- “On 20 May 2026, Vertex Pharmaceuticals (Europe) Limited sold its investment in Vertex Pharmaceuticals (Ireland) Limited to Vertex Pharmaceuticals Ireland Holding Unlimited Company, an indirect subsidiary of Vertex Pharmaceutical Inc., for consideration of $550 million.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
4 active · 20 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| BROOKS, Jason Mark | Director | 2025-08-08 | Jul 1972 | British,Australian |
| LEM, Simon Kempin | Director | 2015-10-05 | Feb 1973 | British |
| THOMBRE, Prasanna Eknath | Director | 2025-08-08 | Jun 1968 | British,American |
| WHITE, Omar Narayan | Director | 2025-08-08 | Jan 1973 | American |
Show 20 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| MITRE SECRETARIES LIMITED | Corporate Nominee Secretary | 1994-03-11 | 2024-05-31 |
| ALDRICH, Richard Holmes | Director | 1994-08-10 | 2000-12-22 |
| ALLAN, Eva Lotta | Director | 2004-07-30 | 2006-05-31 |
| BEDSON, Simon | Director | 2015-10-05 | 2018-10-15 |
| BELLANDI, Michele | Director | 2018-10-15 | 2019-04-19 |
| BRIMBLECOMBE, Roger William, Dr | Director | 2005-07-12 | 2010-07-23 |
| BUCHANAN, Iain Peter Murray | Director | 1994-08-10 | 2004-07-29 |
| EMMENS, Matthew William | Director | 2011-08-02 | 2012-05-22 |
| GOLEC, Julian Marian Charles, Dr | Director | 2002-02-01 | 2011-08-02 |
| GRIST, Ashley Alexander | Director | 2019-04-19 | 2025-07-01 |
| HERCEND, Thiery, Dr | Director | 1998-09-21 | 2002-01-15 |
| HOLMLUND, Klas Alexander | Director | 2019-04-19 | 2021-12-03 |
| LEIDEN, Jeffrey Marc | Director | 2012-05-22 | 2015-10-05 |
| MUELLER, Peter, Dr | Director | 2005-03-01 | 2011-08-02 |
| OPPENHEIM, Jonathan Richard | Director | 2022-02-08 | 2026-08-27 |
| REEVES, Barbara | Nominee Director | 1994-03-11 | 1994-08-10 |
| SATO, Vicki, Dr | Director | 1998-09-21 | 2005-03-01 |
| SMITH, Ian Frederick | Director | 2011-08-02 | 2019-01-23 |
| SMITH, Ian Frederick | Director | 2002-02-01 | 2009-01-01 |
| WINDMILL, Robert John | Nominee Director | 1994-03-11 | 1994-08-10 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Vertex Pharmaceuticals Uk Holdings Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2024-12-31 | Active |
| Vertex Pharmaceuticals Incorporated | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Ceased 2024-12-31 |
Filing timeline
Last 20 of 149 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-09-14 | AA | accounts | Accounts with accounts type full | |
| 2026-09-02 | TM01 | officers | Termination director company with name termination date | |
| 2026-03-24 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-08-19 | AP01 | officers | Appoint person director company with name date | |
| 2025-08-15 | AP01 | officers | Appoint person director company with name date | |
| 2025-08-15 | AP01 | officers | Appoint person director company with name date | |
| 2025-07-11 | AA | accounts | Accounts with accounts type full | |
| 2025-07-07 | TM01 | officers | Termination director company with name termination date | |
| 2025-03-25 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-03-25 | CH01 | officers | Change person director company with change date | |
| 2025-02-19 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2025-02-19 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2024-08-29 | AA | accounts | Accounts with accounts type full | |
| 2024-05-31 | TM02 | officers | Termination secretary company with name termination date | |
| 2024-03-26 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-10-30 | AA | accounts | Accounts with accounts type full | |
| 2023-04-06 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-09-28 | AA | accounts | Accounts with accounts type full | |
| 2022-03-11 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-02-08 | AP01 | officers | Appoint person director company with name date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 3
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.